AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02832336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivarin
Description: Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
Study NCT02832336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fiber
Description: Fiber will be used as placebo.
Study NCT01463202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot medroxyprogesterone acetate
Description: Postpartum administration of DMPA (prior to hospital discharge)
Study NCT01463202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot medroxyprogesterone acetate
Description: Delayed administration of DMPA (4-6 weeks postpartum)
Study NCT02825212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harvoni
Description: 12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: 1 capsule
Study NCT02825212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
Study NCT04003987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20ml
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 Placebo
Description: 2 tablets
Study NCT04003987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, 0.125%
Description: 60ml
Study NCT02122367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)
Description: HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
Study NCT00953940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
Study NCT02581969 — intervention group
Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Administered 20-30 IU/kg 3 times a week
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 30mg tablet
Study NCT00713336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10mg tablet
Study NCT00355862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)
Description: center specific therapeutic regimen without mTOR inhibition
Study NCT00355862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus based immunosuppression
Study NCT01416727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emergency Psychiatry Immersion Course
Description: A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
Study NCT01416727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observed SKills in the Emergency Room
Description: For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
Study NCT03379649 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
Study NCT02581969 — intervention group
Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Administered only for bleeding episodes
Study NCT03379649 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
Study NCT04327219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDED diet
Description: examine the microbial, mucosal and immunological changes of the pouch during one year post IPAA, and examine the impact of the CDED on disease activity and dysbiosis in adults suffering from active pouchitis.
Study NCT03341195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS messages and automated calls
Description: The intervention consists of SMS and automated calls based messages
Study NCT02517996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
Study NCT02517996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
Study NCT04248933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Delivered Behavioral Activation (Peer Activate)
Description: The Peer Activate intervention consisted of weekly one-hour BA sessions led by a peer recovery specialist (PRS) for up to 12 weekly sessions, with the first five being the core treatment sessions and content, and the subsequent seven designed to reinforce core content. In these sessions, participants received individualized support in learning skills to assist in their retention and persistence in methadone treatment and were guided through exercises aimed at incorporating substance-free, rewarding activities into their daily life.
Study NCT03937414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The OSNA assay
Description: SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
Study NCT04128163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1206
Description: subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU
Study NCT04128163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU
Study NCT00492310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: vinyasa yoga
Study NCT00492310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive therapy
Description: cognitive behavioral therapy once weekly
Study NCT00492310 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive therapy
Description: cognitive behavioral therapy once weekly
Study NCT00492310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: vinyasa yoga twice weekly with smoking cessation once weekly
Study NCT00492310 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: wellness
Description: wellness program with smoking cessation
Study NCT04026607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
Study NCT00445965 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Study NCT00445965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study NCT00445965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT03052998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Effect of Ivermectin on frequency of seizures
Study NCT00316121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEALOS and Leopard Cage
Description: Placement in interbody space
Study NCT00316121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leopard Cage and Autograft
Description: Placement in the interbody space
Study NCT02676726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraperitoneal Laparoscopic aortic lymphadenectomy
Description: Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
Study NCT02676726 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal Laparoscopic aortic lymphadenectomy
Description: Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
Study NCT04464499 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG measurement
Description: Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG
Study NCT02770274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Dual therapy with Cilostazol 100 mg twice daily
Study NCT02770274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Monotherapy with aspirin 100 mg once daily
Study NCT02770274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Monotherapy with aspirin 100 mg once daily
Study NCT02428595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse™ System
Description: The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System.
Study NCT02486107 — intervention group
Intervention type: PROCEDURE
Intervention: surgical procedure
Study NCT02681315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC 6 liter minute
Description: Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
Study NCT02681315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHHFNC 3 liters/min
Description: Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
Study NCT02353390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Water Hydration
Description: Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
Study NCT02479139 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle for ANT-1207 liniment formulation without active ingredient.
Study NCT02479139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: Botulinum toxin Type A topical liniment (ANT-1207).
Study NCT01727336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept and axitinib
Study NCT01727336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and axitinib
Study NCT03870425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distribution pattern of dietary proteins (minced meat)
Description: Study effect of an even or skewed distribution pattern of dietary protein
Study NCT03870425 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distribution pattern of dietary proteins (minced meat)
Description: Study effect of an even or skewed distribution pattern of dietary protein
Study NCT03645512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corporate Athlete Resilience (CAR) Training Program
Description: A 1-day training program developed by the J\&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
Study NCT04515108 — intervention group
Intervention type: OTHER
Intervention: Clinical assessment
Description: Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.
Study NCT05172804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement \[11\].
Study NCT05172804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin \[11\].
Study NCT05172804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction... how interesting) \[11\].
Study NCT05172804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants in the control condition will be instructed to sit with their eyes closed and relax during the intervention periods. Participants in the control group will follow an identical procedure and time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
Study NCT02547051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Allergy Testing and Elimination Diet
Description: Food allergy testing and elimination diet
Study NCT02336542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Description: TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
Study NCT02336542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Description: TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
Study NCT02336542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm
Description: TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
Study NCT02336542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm
Description: TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
Study NCT02336542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Description: TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
Study NCT02336542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Description: TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
Study NCT02336542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm
Description: TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
Study NCT02336542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm
Description: TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
Study NCT02690714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasminogen (Human) intravenous
Description: Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
Study NCT01873651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of a Delta III Prosthesis
Description: Implantation of a Delta III Prosthesis
Study NCT04117698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antitubercular treatment (RIFATER ©)
Description: Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group.
Study NCT04117698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol
Study NCT04117698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIFINAH ©
Description: RIFINAH ©